Reportlinker Adds Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

NEW YORK, Aug. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

http://www.reportlinker.com/p0284989/Competitive-Outlook-on-Lung-Cancer-Drug-Development---The-Missing-Handbook-to-New-Product-Planning-and-Portfolio-Planning.html

This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies' portfolio planning and new product planning by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting lung cancer sub-indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights 4

3 Methodologies 6

4 Table of Contents 8

4.1 List of Figures 18

4.2 List of Tables 19

5 Introduction 27

5.1 The Scope of this Report 27

5.2 Definitions 30

5.3 Abbreviations 30

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 31

6.1 Drug Repositioning in Oncology 31

6.2 Introduction to Lung Cancer Drug Targets 32

6.2.1 Carboxy-lyase Activity Targets 34

6.2.2 Catalytic ActivityTargets 35

6.2.3 Cell Adhesion Molecule Activity Targets 37

6.2.4 Chaperone ActivityTargets 43

6.2.5 Chemokine Activity Targets 46

6.2.6 Complement Activity Targets 48

6.2.7 Cysteine-Type Peptidase Activity Targets 49

6.2.8 Cytokine Activity Targets 54

6.2.9 DNA Binding Targets 60

6.2.10 DNA Repair Protein Targets 61

6.2.11 DNA Topoisomerase Activity Targets 63

6.2.12 DNA-Directed DNA Polymerase Activity Targets 67

6.2.13 DNA-methyltransferase Activity Targets 73

6.2.14 Extracellular Ligand-Gated Ion Channel Activity Targets 74

6.2.15 Extracellular Matrix Structural Constituent Targets 75

6.2.16 G-protein Coupled Receptor Activity Targets 76

6.2.17 Glutathione Transferase Activity Targets 81

6.2.18 Growth Factor Activity Targets 82

6.2.19 GTPase Activity Targets 85

6.2.20 Hormone activity Targets 92

6.2.21 Hydrolase Activity Targets 93

6.2.22 Ion channel Activity Targets 94

6.2.23 Kinase Activity Targets 95

6.2.24 Kinase regulator activity Targets 101

6.2.25 Ligase Activity Targets 102

6.2.26 Lipase Activity Targets 105

6.2.27 Lipid Kinase Activity Targets 106

6.2.28 Metallopeptidase Activity Targets 107

6.2.29 Molecular Function Unknown Targets 110

6.2.30 Motor Activity Targets 116

6.2.31 Oxidoreductase Activity Targets 117

6.2.32 Peptidase Activity Targets 120

6.2.33 Peroxidase Activity Targets 122

6.2.34 Phosphoric Diester Hydrolase Activity Targets 123

6.2.35 Protein binding Targets 125

6.2.36 Protein Serine/Threonine Kinase Activity Targets 126

6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets 142

6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 145

6.2.39 Protein-Tyrosine Kinase Activity Targets 146

6.2.40 Receptor Activity Targets 156

6.2.41 Receptor binding Targets 167

6.2.42 Receptor Signaling Complex Scaffold Activity Targets 170

6.2.43 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 173

6.2.44 RNA Binding Targets 174

6.2.45 RNA-Directed DNA Polymerase Activity Targets 175

6.2.46 Serine-Type Peptidase Activity Targets 176

6.2.47 Structural Constituent of Cytoskeleton Targets 179

6.2.48 Transcription Factor Activity Targets 181

6.2.49 Transcription Regulator Activity Targets 195

6.2.50 Transcription Regulator Activity Targets 200

6.2.51 Transferase Activity Targets 201

6.2.52 Transmembrane Receptor Activity Targets 203

6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 205

6.2.54 Transporter Activity Targets 241

6.2.55 Ubiquitin-Specific Protease Activity Targets 246

6.2.56 Other Targets 247

6.3 The Cancer Genome Project and Lung Cancer Targets 248

6.3.1 Lung Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 248

6.4 Structure-based Drug Design in Lung Cancer is Stimulated by Available Structure Data on Biological Targets 252

6.5 Target-Target Interactions among Identified Lung Cancer Targets 256

6.6 The Drug-Target Interactome 261

6.7 Protein Expression Levels of Identified Drug Targets of Lung Cancer Drugs 266

6.8 Pathway Analysis of Lung Cancer Drug Targets 274

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? 324

7.1 Terminated Drug Target Profiles in Lung Cancer 327

7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 330

7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 331

7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lung Cancer Pipeline 333

7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 338

7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 342

7.7 Development Profiles of All Lung Cancer Drug Target Profiles 344

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound 369

8.1 Small Molecules 371

8.1.1 Background 371

8.1.2 Targets in Lung Cancer 372

8.2 Peptide/Protein Drugs 386

8.2.1 Background 386

8.2.2 Targets in Lung Cancer 387

8.3 Antibodies and Antibody-like Structures 391

8.3.1 Background 391

8.3.2 Targets in Lung Cancer 391

8.4 Nucleic Acid Therapies 395

8.4.1 Background 395

8.4.2 Targets in Lung Cancer 396

8.5 Gene Therapy 398

8.5.1 Background 398

8.5.2 Targets in Lung Cancer 398

8.6 Drug Delivery and Nanotechnology 401

8.6.1 Background 401

8.6.2 Targets in Lung Cancer 401

8.7 The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer 404

8.8 Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 411

9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420

9.1 Lung Cancer (general) 421

9.1.1 Players and their Compared Pipeline 421

9.1.2 Where is the Real Competition? 426

9.1.3 How Successful are They in Their Targeting Strategy? 428

9.2 Non-Small Cell Lung Cancer 430

9.2.1 Players and their Compared Pipeline 430

9.2.2 Where is the Real Competition? 442

9.2.3 How Successful are They in Their Targeting Strategy? 446

9.3 Small Cell Lung Cancer 455

9.3.1 Players and their Compared Pipeline 455

9.3.2 Where is the Real Competition? 460

9.3.3 How Successful are They in Their Targeting Strategy? 461

10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator 463

10.1 Abbott 465

10.2 Abraxis BioScience 468

10.3 Active Biotech 470

10.4 Adherex 471

10.5 Advantagene 472

10.6 AEgera 473

10.7 Aeterna Zentaris 474

10.8 Agennix 476

10.9 Aida Pharmaceuticals 477

10.10 Alchemia 478

10.11 Alethia Biotherapeutics 480

10.12 Allos Therapeutics 481

10.13 Amgen 482

10.14 Antisense Pharma 485

10.15 Antisoma 486

10.16 Anza Therapeutics 487

10.17 ApopLogic Pharmaceuticals 488

10.18 Archer Biosciences 490

10.19 Ariad 492

10.20 ArQule 494

10.21 Array BioPharma 496

10.22 Ascenta Therapeutics 497

10.23 Astellas 498

10.24 AstraZeneca 499

10.25 Bayer 502

10.26 Biogen Idec 505

10.27 Biokine Therapeutics 507

10.28 BioNumerik 508

10.29 Boehringer Ingelheim 510

10.30 Bristol-Myers Squibb 512

10.31 BTG 519

10.32 CanBas 521

10.33 Celator Pharmaceuticals 522

10.34 Cell Genesys 524

10.35 Cell Therapeutics 525

10.36 Celtic Pharma 528

10.37 Center of Molecular Immunology 529

10.38 Cephalon 531

10.39 CG Therapeutics 532

10.40 Chemokine Therapeutics 533

10.41 Chong Kun Dang 534

10.42 Clavis Pharma 536

10.43 CLL Pharma 537

10.44 Critical Outcome Technologies 539

10.45 Cyclacel 540

10.46 CytImmune Sciences 541

10.47 Cytokinetics 542

10.48 Dabur Pharma 543

10.49 Daiichi Sankyo 545

10.50 Dainippon Sumitomo Pharma 548

10.51 Dara Biosciences 550

10.52 Dendreon 551

10.53 Dong-A 553

10.54 Eisai 555

10.55 Eli Lilly 557

10.56 Endocyte 560

10.57 EntreMed 561

10.58 EpiCept 562

10.59 Exelixis 564

10.60 Galapagos 568

10.61 Gemin X Pharmaceuticals 569

10.62 Genentech 570

10.63 Genmab 573

10.64 Genta 575

10.65 GenVec 577

10.66 Genzyme 578

10.67 Geron 579

10.68 GlaxoSmithKline 580

10.69 GlobeImmune 584

10.70 GlycoGenesys 585

10.71 Hana Biosciences 586

10.72 Hoffmann-La Roche 587

10.73 Human Genome Sciences 588

10.74 Idera Pharmaceuticals 589

10.75 ImClone Systems 590

10.76 ImmunoCellular Therapeutics 593

10.77 Immunocore 594

10.78 ImmunoGen 596

10.79 Immunomedics 598

10.80 Incyte Corporation 601

10.81 Infinity Pharmaceuticals 602

10.82 Innovive 603

10.83 Inovio 605

10.84 Introgen Therapeutics 606

10.85 Ipsen 608

10.86 Isis Pharmaceuticals 610

10.87 Jennerex Biotherapeutics 611

10.88 Johnson & Johnson 612

10.89 Kiadis 615

10.90 Kyowa Hakko Kirin 617

10.91 Lorus Therapeutics 620

10.92 MacroGenics 621

10.93 Medarex 622

10.94 MediGene 624

10.95 Medisyn Technologies 625

10.96 Menarini 627

10.97 Merck KGaA 629

10.98 MethylGene 632

10.99 Micromet 634

10.100 Mirna Therapeutics 636

10.101 MolMed 637

10.102 Mologen 638

10.103 Nektar Therapeutics 639

10.104 NeoPharm 641

10.105 Nerviano Medical Sciences 644

10.106 Novacea 646

10.107 Novartis 647

10.108 OncoGenex Pharmaceuticals 652

10.109 Oncothyreon 655

10.110 OSI Pharmaceuticals 656

10.111 OXiGENE 660

10.112 PanaGin 661

10.113 PBL Therapeutics 662

10.114 PDL BioPharma 663

10.115 Pfizer 664

10.116 Pharmacyclics 669

10.117 PharmaGap 670

10.118 PharmaMar 671

10.119 Pharmexa 674

10.120 Pierre Fabre 676

10.121 Pro-Pharmaceuticals 677

10.122 Progen 678

10.123 Protox Therapeutics 679

10.124 Receptor BioLogix 680

10.125 Regulon 682

10.126 RESprotect 683

10.127 Samyang 684

10.128 Sanofi-Aventis 687

10.129 Sareum 690

10.130 Schering-Plough 692

10.131 Seattle Genetics 693

10.132 ShimodaAtlantic Oncology 694

10.133 Shire 695

10.134 Sigma-Tau 696

10.135 Simcere Pharmaceuticals 698

10.136 SRI International 699

10.137 SuperGen 700

10.138 Supratek Pharma 703

10.139 Switch Pharma 706

10.140 Taiho 707

10.141 Takeda 709

10.142 Taxolog 711

10.143 Tekmira Pharmaceuticals 714

10.144 Telik 716

10.145 Thallion Pharmaceuticals 717

10.146 Therion Biologics 719

10.147 Titan Pharmaceuticals 720

10.148 Tracon Pharmaceuticals 722

10.149 Tragara Pharmaceuticals 723

10.150 Transgene 724

10.151 Trion Pharma 726

10.152 Twinstrand Therapeutics 727

10.153 UCB 728

10.154 Valeant 730

10.155 Vaxon Biotech 731

10.156 Vertex Pharmaceuticals 732

10.157 Vion Pharmaceuticals 733

10.158 ViRexx 735

10.159 Voyager Pharmaceutical 736

10.160 Wilex 737

10.161 Wyeth 738

10.162 Xerion 742

10.163 Xoma 744

10.164 Yakult Honsha 745

10.165 YM BioSciences 747

10.166 Zivena 749

10.167 Non-industrial Organizations 751

11 Disclaimer 752

12 Drug Index 753

13 Company Index 761

4.1 List of Figures

Figure 1: Overall Breakdown of the Included Lung Cancer Therapeutic Pipeline by Sub-Indication and Stage of Development 27

Figure 2: Visualization of Target-Target Interactions Among Lung Cancer Drug Targets 260

Figure 3: The Drug-Protein Interactome of Lung Cancer Drugs –Clusters I 263

Figure 4: The Drug-Protein Interactome of Lung Cancer Drugs – Clusters II 264

Figure 5: Head-to-Head Targeting Interactome of Lung Cancer Drugs 265

Figure 6: Distribution of Compound Types among Lung Cancer Drugs 411

Figure 7: Primary Sub-cellular Localization of Drug Targets 412

Figure 8: Breakdown of the Lung Cancer (general) Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 424

Figure 9: Compound Strategy Breakdown of the Lung Cancer (general) Pipeline 425

Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 439

Figure 11: Compound Strategy Breakdown of the Non-Small Cell Lung Cancer Pipeline 441

Figure 12: Breakdown of the Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development 458

Figure 13: Compound Strategy Breakdown of the Small Cell Lung Cancer Pipeline 459

4.2 List of Tables

Table 1: Competitive Pressure Force Among Lung Cancer Drugs 26

Table 2: Overview of Drug Target Profile Themes 31

Table 3: Terminally Ceased Therapeutic Lung Cancer Targets 32

Table 4: Drug Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 248

Table 5: Identity of Lung Cancer Drug Targets with Available Biological Structures 252

Table 6: Number of Target-Target Interactions among Lung Cancer Drug Targets 255

Table 7: Drug-Protein Interactome Clusters 260

Table 8: Lung Cancer Drug Targets with Available Protein Expression Profiles 265

Table 9: Expression Levels of Identified Drug Targets in Lung Cancer Tissue 269

Table 10: Pathway Summary 273

Table 11: Drug Targets without any Identified Assigned Pathways 273

Table 12: Pathway Profile According to BioCarta of Lung Cancer Drug Targets 274

Table 13: Pathway Profile According to KEGG of Lung Cancer Drug Targets 297

Table 14: Pathway Profile According to NetPath of Lung Cancer Drug Targets 318

Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness 323

Table 16: Top Competitive Lung Cancer Target Profiles 324

Table 17: Terminated Drug Target Strategies in Lung Cancer 326

Table 18 New and Unique Lung Cancer Target Strategies in Pre-Registration to Marketed 329

Table 19: New and Unique Lung Cancer Target Strategies in Phase III Clinical Development 330

Table 20: New and Unique Lung Cancer Target Strategies in Phase II Clinical Development 332

Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs 335

Table 22 New and Unique Lung Cancer Target Strategies in Phase I Clinical Development 337

Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 339

Table 24: New and Unique Lung Cancer Target Strategies in Preclinical Development 341

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs 342

Table 26: The Progression, Maturity and Competitive Comparison of Lung Cancer Drug Target Profiles in Development 343

Table 27: Overview of Compound Strategy Competition in Lung Cancer 369

Table 28:Overview of the Competitive Landscape of Small Molecular Drugs in Lung Cancer 371

Table 29: Head-to-Head Target Competition Between Small Molecule Drugs for the Treatment of Lung Cancer 372

Table 30: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lung Cancer 373

Table 31: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Lung Cancer Drugs in Development 376

Table 32: Overview of the Competitive Landscape of Peptide Based Drugs in Lung Cancer 386

Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Lung Cancer Drug in Development 386

Table 34:Overview of the Competitive Landscape of Protein Based Drugs in Lung Cancer 387

Table 35: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lung Cancer 388

Table 36: The Progression, Maturity and Competitive Comparison of Protein Based Lung Cancer Drug Target Profiles in Development 388

Table 37:Overview of the Competitive Landscape of Antibody Drugs in Lung Cancer 390

Table 38: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lung Cancer 391

Table 39: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Lung Cancer Drugs in Development 392

Table 40:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lung Cancer 395

Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Lung Cancer Drugs in Development 395

Table 42: Vectors in Gene Therapy 397

Table 43:Overview of the Competitive Landscape of Gene Therapy Drugs in Lung Cancer 397

Table 44: The Competition Through Close Mechanistic Approximation Between Gene Therapy Drugs in Lung Cancer 398

Table 45: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Lung Cancer Drugs in Development 398

Table 46:Overview of the Competitive Landscape of Reformulated Drugs in Lung Cancer 400

Table 47: The Competition Through Close Mechanistic Approximation Between Reformulated Drugs in Lung Cancer 401

Table 48: The Progression, Maturity and Competitive Comparison of Target Profiles of Reformulated Lung Cancer Drugs in Development 401

Table 49: The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer 403

Table 50: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 411

Table 51: Competitive Summary of Lung Cancer Drugs by Sub-Indication 419

Table 52: Players in the Field of Lung Cancer (general) Drug Development and their Compared Pipeline 420

Table 53: The Competition Through Close Mechanistic Approximation Between Lung Cancer (general) Drugs 425

Table 54: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lung Cancer (general) Drug Development 427

Table 55: Players in the Field of Non-Small Cell Lung Cancer Drug Development and their Compared Pipeline 429

Table 56: The Competition Through Close Mechanistic Approximation Between Non-Small Cell Lung Cancer Drugs 441

Table 57: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Small Cell Lung Cancer Drug Development 445

Table 58: Players in the Field of Small Cell Lung Cancer Drug Development and their Compared Pipeline 454

Table 59: The Competition Through Close Mechanistic Approximation Between Small Cell Lung Cancer Drugs 459

Table 60: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Small Cell Lung Cancer Drug Development 460

Table 61: Abbott's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 464

Table 62: Abraxis BioScience's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 467

Table 63: Active Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 469

Table 64: Adherex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 470

Table 65: Advantagene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 471

Table 66: AEgera's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 472

Table 67: Aeterna Zentaris' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 473

Table 68: Agennix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 475

Table 69: Aida Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 476

Table 70: Alchemia's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 477

Table 71: Alethia Biotherapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 479

Table 72: Allos Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 480

Table 73: Amgen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 481

Table 74: Antisense Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 484

Table 75: Antisoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 485

Table 76: Anza Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 486

Table 77: ApopLogic Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 487

Table 78: Archer Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 489

Table 79: Ariad's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 491

Table 80: ArQule's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 493

Table 81: Array BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 495

Table 82: Ascenta Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 496

Table 83: Astellas' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 497

Table 84: AstraZeneca's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 498

Table 85: Bayer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 501

Table 86: Biogen Idec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 504

Table 87: Biokine Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 506

Table 88: BioNumerik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 507

Table 89: Boehringer Ingelheim's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 509

Table 90: Bristol-Myers Squibb's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 511

Table 91: BTG's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 518

Table 92: CanBas' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 520

Table 93: Celator Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 521

Table 94: Cell Genesys' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 523

Table 95: Cell Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 524

Table 96: Celtic Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 527

Table 97: Center of Molecular Immunology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 528

Table 98: Cephalon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 530

Table 99: CG Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 531

Table 100: Chemokine Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 532

Table 101: Chong Kun Dang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 533

Table 102: Clavis Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 535

Table 103: CLL Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 536

Table 104: Critical Outcome Technologies' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 538

Table 105: Cyclacel's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 539

Table 106: CytImmune Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 540

Table 107: Cytokinetics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 541

Table 108: Dabur Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 542

Table 109: Daiichi Sankyo's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 544

Table 110: Dainippon Sumitomo Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 547

Table 111: Dara Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 549

Table 112: Dendreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 550

Table 113: Dong-A's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 552

Table 114: Eisai's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 554

Table 115: Eli Lilly's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 556

Table 116: Endocyte's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 559

Table 117: EntreMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 560

Table 118: EpiCept's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 561

Table 119: Exelixis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 563

Table 120: Galapagos' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 567

Table 121: Gemin X Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 568

Table 122: Genentech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 569

Table 123: Genmab's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 572

Table 124: Genta's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 574

Table 125: GenVec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 576

Table 126: Genzyme's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 577

Table 127: Geron's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 578

Table 128: GlaxoSmithKline's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 579

Table 129: GlobeImmune's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 583

Table 130: GlycoGenesys' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 584

Table 131: Hana Biosciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 585

Table 132: Hoffmann-La Roche's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 586

Table 133: Human Genome Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 587

Table 134: Idera Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 588

Table 135: ImClone Systems' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 589

Table 136: ImmunoCellular Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 592

Table 137: Immunocore's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 593

Table 138: ImmunoGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 595

Table 139: Immunomedics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 597

Table 140: Incyte Corporation's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 600

Table 141: Infinity Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 601

Table 142: Innovive's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 602

Table 143: Inovio's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 604

Table 144: Introgen Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 605

Table 145: Ipsen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 607

Table 146: Isis Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 609

Table 147: Jennerex Biotherapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 610

Table 148: Johnson & Johnson's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 611

Table 149: Kiadis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 614

Table 150: Kyowa Hakko Kirin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 616

Table 151: Lorus Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 619

Table 152: MacroGenics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 620

Table 153: Medarex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 621

Table 154: MediGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 623

Table 155: Medisyn Technologies' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 624

Table 156: Menarini's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 626

Table 157: Merck KGaA's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 628

Table 158: MethylGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 631

Table 159: Micromet's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 633

Table 160: Mirna Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 635

Table 161: MolMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 636

Table 162: Mologen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 637

Table 163: Nektar Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 638

Table 164: NeoPharm's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 640

Table 165: Nerviano Medical Sciences' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 643

Table 166: Novacea's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 645

Table 167: Novartis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 646

Table 168: OncoGenex Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 651

Table 169: Oncothyreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 654

Table 170: OSI Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 655

Table 171: OXiGENE's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 659

Table 172: PanaGin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 660

Table 173: PBL Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 661

Table 174: PDL BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 662

Table 175: Pfizer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 663

Table 176: Pharmacyclics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 668

Table 177: PharmaGap's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 669

Table 178: PharmaMar's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 670

Table 179: Pharmexa's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 673

Table 180: Pierre Fabre's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 675

Table 181: Pro-Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 676

Table 182: Progen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 677

Table 183: Protox Therapeutics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 678

Table 184: Receptor BioLogix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 679

Table 185: Regulon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 681

Table 186: RESprotect's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 682

Table 187: Samyang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 683

Table 188: Sanofi-Aventis' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 686

Table 189: Sareum's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 689

Table 190: Schering-Plough's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 691

Table 191: Seattle Genetics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 692

Table 192: ShimodaAtlantic Oncology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 693

Table 193: Shire's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 694

Table 194: Sigma-Tau's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 695

Table 195: Simcere Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 697

Table 196: SRI International's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 698

Table 197: SuperGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 699

Table 198: Supratek Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 702

Table 199: Switch Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 705

Table 200: Taiho's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 706

Table 201: Takeda's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 708

Table 202: Taxolog's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 710

Table 203: Tekmira Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 713

Table 204: Telik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out 715

Table 205: Thallion Pharmaceuticals' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 716

Table 206: Therion Biologics' Included Lung Cancer Pipeline Composition and Competitive Fall-Out 718

Tabl

To order this report:

Biotechnology Industry: Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker